Nausea and Vomiting

Question 1

High ematogenicity for IV chemotherapy

Accepted Answer

>90%

Question 2

Medium ematogenicity for IV chemotherapy

Accepted Answer

30-90%

Question 3

low ematogenicity for IV chemotherapy

Accepted Answer

10-30%

Question 4

Minimal ematogenicity for IV chemotherapy

Accepted Answer

<10%

Question 5

Moderate to high ematogenicity for oral chemotherapy

Accepted Answer

>30%

Question 6

Minimal-low ematogenicity for oral chemotherapy

Accepted Answer

<30%

Question 7

CINV risk factors

Accepted Answer

<50 years old female history of morning sickness/motion sickness history of poor CINV control depression/anxiety

Question 8

CINV acute phase

Accepted Answer

enterocromaffin cells of GI tract damaged, serotonin release, activate 5HT3 receptors to cause NV

Question 9

CINV delayed phase

Accepted Answer

dopamine/substance p release activating NK1 receptors to cause NV

Question 10

CINV high risk gold standard prevention

Accepted Answer

Quadruplet therapy 5HT3RA dexamethasone NK1RA olanzapine all given day 1, olanzapine and dexamethasone continued days 2-4

Question 11

CINV med risk gold standard

Accepted Answer

double therapy 5HT3RA dexamethasone either one continued for 2-3 days

Question 12

CINV low risk gold standard

Accepted Answer

5HT3RA or dexamethasone given one time for prevention of acute NV

Question 13

CINV high to moderate oral gold standard

Accepted Answer

5HT3RA daily

Question 14

CINV low-med oral gold standard

Accepted Answer

metaclopramide prochlorperazine or 5HT3RA daily as needed

Question 15

treatment for anticipatory CINV

Accepted Answer

lorazepam

Question 16

What are the drugs that end in "pitant"?

Accepted Answer

NK1RAs, used for high emesis chemotherapy. Aprepitant, rolapitant, etc

Question 17

Max IV dose of ondansetron?

Accepted Answer

16mg

Alle Karten